



Biotech Company Expects Preclinical Drug Results on Curing Addiction.

Orlando, FL July 1, 2022: ACT Sciences (**Addiction Cure Therapeutic Sciences Inc**) an international Rx solution company targeting drug and alcohol addiction cures and treatments, announced today it expects to receive the results of its first preclinical trial on one of its epigenetic compounds for the treatment of drug addiction within 60 days.

Dr. Alex Federation, one of ACT SCIENCES premier scientists and the catalyst for experimenting with Epigenetics said, “much of my career has been spent looking for a cure for cancer and I believe we are on the verge of accomplishing great things in that area. Working with ACT SCIENCES I have seen how some compounds/molecules we experimented with in cancer research could translate into potential addiction cures, so I’m looking forward to seeing our results with great hope and optimism.”

Nearly all current treatments for substance abuse target the signaling chemicals neurons used to communicate, however ACTS Scientists are exploring the underlying epigenetic causes. In a search of 240 active pharmaceutical programs in the addiction space, nearly all were focused on molecules that directly alter brain-signaling molecules like dopamine and opiate receptors. Only 10 out of 240 programs focused on a drug target which isn’t directly involved in neurochemical pathways; none of these 10 focused on epigenetic or gene regulation as a mechanism to treat the disease.

Jack Levine ACT SCIENCES CEO said “We are excited to see the results of the first epigenetic compound we have submitted for testing and our Scientists are prepared to



proceed with a handful of others,” said Jack Levine ACT SCIENCES CEO. “Our mission and purpose is to find a cure for drug and alcohol addiction. We have been working hard for 2 years to bring together top scientists to research, develop, and test new breakthrough cures, and we hope our efforts will put an end to the scourge of addiction that is ruining our families hopes, dreams, and lives and destroying the futures of our children”.

Over 25 Million People in America suffer from Drug Addiction, and this number has been growing for decades, recently accelerating at unprecedented rates. With fentanyl and other drugs freely moving into our Country, experts are predicting that the U.S. addiction problem will only grow larger and faster than ever before.

About ACT SCIENCES INC - Addiction Cure Therapeutic Sciences Inc. is a biotech firm advancing first in class therapeutics to treat and cure the devastating disease of drug and alcohol addiction. ACT Sciences is committed to discovering life-changing treatments and cures that transform the lives of people struggling with drug and alcohol addiction. The Company is developing products designed to provide long-term benefit or a functional cure for addiction. ACTS’ Scientists and Physicians are working towards a FDA approved Rx cure for chemical addiction. Additionally, the Company is presently pursuing a parallel path using compound drugs as a quicker to-market strategy, and test platform to finding a cure. For more information, please visit www.actsciencesinc.com

Forward-Looking Statements

The statements made by ADDICTION CURE THERAPEUTIC SCIENCES Inc., in this press release may be “forward-looking” in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe ACT Sciences’ future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of ADDICTION CURE THERAPEUTIC SCIENCES, Inc. Actual results could differ materially from those projected due to there being no assurance that our addiction fighting candidates will be successfully shown to combat addiction, that the addiction candidate will be approved for use by the U.S. FDA or any equivalent foreign regulatory agency, that the addiction candidate can be manufactured in large quantities or that third parties with an established presence in The Addiction Community, vaccine development, employer or individual



use will enter into agreements or purchase from the Company, and even if the Company's addiction candidate is successful, it may generate only limited revenue and profits for the Company, including whether any of ACT Sciences' products will receive clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to sell its products and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, the fact that there has never been a chemical cure for chemical addiction approved for use and various other factors detailed from time to time in ACT Sciences' SEC reports and filings, including our Annual Reports and our subsequent quarterly reports, and other reports we file with the SEC, which are available at www.sec.gov. ADDICTION CURE THERAPEUTIC SCIENCES, INC. undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.

ACT Sciences Corporate Contact:

MIKE LAMBERT

CMO

P. 954-684-4782

MDL@ACTSCIENCESINC.COM